194 related articles for article (PubMed ID: 24474032)
1. Chimeric cytochromes P450 engineered by domain swapping and random mutagenesis for producing human metabolites of drugs.
Kang JY; Ryu SH; Park SH; Cha GS; Kim DH; Kim KH; Hong AW; Ahn T; Pan JG; Joung YH; Kang HS; Yun CH
Biotechnol Bioeng; 2014 Jul; 111(7):1313-22. PubMed ID: 24474032
[TBL] [Abstract][Full Text] [Related]
2. Regioselective hydroxylation of 17β-estradiol by mutants of CYP102A1 from Bacillus megaterium.
Cha GS; Ryu SH; Ahn T; Yun CH
Biotechnol Lett; 2014 Dec; 36(12):2501-6. PubMed ID: 25129047
[TBL] [Abstract][Full Text] [Related]
3. The bacterial P450 BM3: a prototype for a biocatalyst with human P450 activities.
Yun CH; Kim KH; Kim DH; Jung HC; Pan JG
Trends Biotechnol; 2007 Jul; 25(7):289-98. PubMed ID: 17532492
[TBL] [Abstract][Full Text] [Related]
4. Construction of a thermostable cytochrome P450 chimera derived from self-sufficient mesophilic parents.
Eiben S; Bartelmäs H; Urlacher VB
Appl Microbiol Biotechnol; 2007 Jul; 75(5):1055-61. PubMed ID: 17468867
[TBL] [Abstract][Full Text] [Related]
5. Preparation of human metabolites of propranolol using laboratory-evolved bacterial cytochromes P450.
Otey CR; Bandara G; Lalonde J; Takahashi K; Arnold FH
Biotechnol Bioeng; 2006 Feb; 93(3):494-9. PubMed ID: 16224788
[TBL] [Abstract][Full Text] [Related]
6. Engineering bacterial cytochrome P450 (P450) BM3 into a prototype with human P450 enzyme activity using indigo formation.
Park SH; Kim DH; Kim D; Kim DH; Jung HC; Pan JG; Ahn T; Kim D; Yun CH
Drug Metab Dispos; 2010 May; 38(5):732-9. PubMed ID: 20100815
[TBL] [Abstract][Full Text] [Related]
7. Generation of human chiral metabolites of simvastatin and lovastatin by bacterial CYP102A1 mutants.
Kim KH; Kang JY; Kim DH; Park SH; Park SH; Kim D; Park KD; Lee YJ; Jung HC; Pan JG; Ahn T; Yun CH
Drug Metab Dispos; 2011 Jan; 39(1):140-50. PubMed ID: 20962060
[TBL] [Abstract][Full Text] [Related]
8. Application of engineered cytochrome P450 mutants as biocatalysts for the synthesis of benzylic and aromatic metabolites of fenamic acid NSAIDs.
Venkataraman H; Verkade-Vreeker MC; Capoferri L; Geerke DP; Vermeulen NP; Commandeur JN
Bioorg Med Chem; 2014 Oct; 22(20):5613-20. PubMed ID: 24999003
[TBL] [Abstract][Full Text] [Related]
9. Application of drug metabolising mutants of cytochrome P450 BM3 (CYP102A1) as biocatalysts for the generation of reactive metabolites.
Damsten MC; van Vugt-Lussenburg BM; Zeldenthuis T; de Vlieger JS; Commandeur JN; Vermeulen NP
Chem Biol Interact; 2008 Jan; 171(1):96-107. PubMed ID: 17996858
[TBL] [Abstract][Full Text] [Related]
10. Expression, purification, and characterization of Bacillus subtilis cytochromes P450 CYP102A2 and CYP102A3: flavocytochrome homologues of P450 BM3 from Bacillus megaterium.
Gustafsson MC; Roitel O; Marshall KR; Noble MA; Chapman SK; Pessegueiro A; Fulco AJ; Cheesman MR; von Wachenfeldt C; Munro AW
Biochemistry; 2004 May; 43(18):5474-87. PubMed ID: 15122913
[TBL] [Abstract][Full Text] [Related]
11. Control of the stereo-selectivity of styrene epoxidation by cytochrome P450 BM3 using structure-based mutagenesis.
Huang WC; Cullis PM; Raven EL; Roberts GC
Metallomics; 2011 Apr; 3(4):410-6. PubMed ID: 21240430
[TBL] [Abstract][Full Text] [Related]
12. A panel of cytochrome P450 BM3 variants to produce drug metabolites and diversify lead compounds.
Sawayama AM; Chen MM; Kulanthaivel P; Kuo MS; Hemmerle H; Arnold FH
Chemistry; 2009 Nov; 15(43):11723-9. PubMed ID: 19774562
[TBL] [Abstract][Full Text] [Related]
13. Active site substitution A82W improves the regioselectivity of steroid hydroxylation by cytochrome P450 BM3 mutants as rationalized by spin relaxation nuclear magnetic resonance studies.
Rea V; Kolkman AJ; Vottero E; Stronks EJ; Ampt KA; Honing M; Vermeulen NP; Wijmenga SS; Commandeur JN
Biochemistry; 2012 Jan; 51(3):750-60. PubMed ID: 22208729
[TBL] [Abstract][Full Text] [Related]
14. Efficient screening of cytochrome P450 BM3 mutants for their metabolic activity and diversity toward a wide set of drug-like molecules in chemical space.
Reinen J; van Leeuwen JS; Li Y; Sun L; Grootenhuis PD; Decker CJ; Saunders J; Vermeulen NP; Commandeur JN
Drug Metab Dispos; 2011 Sep; 39(9):1568-76. PubMed ID: 21673132
[TBL] [Abstract][Full Text] [Related]
15. Engineering a self-sufficient Mycobacterium tuberculosis CYP130 by gene fusion with the reductase-domain of CYP102A1 from Bacillus megaterium.
Ortega Ugalde S; Luirink RA; Geerke DP; Vermeulen NPE; Bitter W; Commandeur JNM
J Inorg Biochem; 2018 Mar; 180():47-53. PubMed ID: 29232638
[TBL] [Abstract][Full Text] [Related]
16. Generation of human metabolites of 7-ethoxycoumarin by bacterial cytochrome P450 BM3.
Kim DH; Kim KH; Kim DH; Liu KH; Jung HC; Pan JG; Yun CH
Drug Metab Dispos; 2008 Nov; 36(11):2166-70. PubMed ID: 18669587
[TBL] [Abstract][Full Text] [Related]
17. Modulation of the interaction between human P450 3A4 and B. megaterium reductase via engineered loops.
Castrignanò S; D'Avino S; Di Nardo G; Catucci G; Sadeghi SJ; Gilardi G
Biochim Biophys Acta Proteins Proteom; 2018 Jan; 1866(1):116-125. PubMed ID: 28734977
[TBL] [Abstract][Full Text] [Related]
18. P450(BM3) (CYP102A1): connecting the dots.
Whitehouse CJ; Bell SG; Wong LL
Chem Soc Rev; 2012 Feb; 41(3):1218-60. PubMed ID: 22008827
[TBL] [Abstract][Full Text] [Related]
19. Generation of the human metabolite piceatannol from the anticancer-preventive agent resveratrol by bacterial cytochrome P450 BM3.
Kim DH; Ahn T; Jung HC; Pan JG; Yun CH
Drug Metab Dispos; 2009 May; 37(5):932-6. PubMed ID: 19237510
[TBL] [Abstract][Full Text] [Related]
20. Human P450-like oxidation of diverse proton pump inhibitor drugs by 'gatekeeper' mutants of flavocytochrome P450 BM3.
Butler CF; Peet C; McLean KJ; Baynham MT; Blankley RT; Fisher K; Rigby SE; Leys D; Voice MW; Munro AW
Biochem J; 2014 Jun; 460(2):247-59. PubMed ID: 24588219
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
